News
Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding unexpectedly well to treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback